Search Results
Jun 26, 2025, 13:53 ET Flacidez facial? Descubra as últimas novidades em tratamentos para recuperar a firmeza da pele do rosto
al. Histological changes with extracellular matrix-remodeling topical therapy. Dermatol Case Rep 2017. 12. Widgerow et al. Gene expression studies on extracellular matrix integrity: in vitro nuances. J Drugs Dermatol 2019. 13. RD.27.SPR.206849
More news about: Galderma
Jun 26, 2025, 13:44 ET Pharmaceutical Cold Storage Market to Reach $34.5 Billion by 2035, Growing at a CAGR of 6.9% from 2025, Says Meticulous Research®
by increasing development of mRNA vaccines and cell & gene therapies. Based on application, Commercial Drug Manufacturing and Distribution accounts for approximately 35% of the market in 2025, while the Biologics and Cell & Gene Therapy Storage segment is projected to record the highest
More news about: Meticulous Market Research Pvt Ltd.
Jun 26, 2025, 10:04 ET SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS
company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its gene therapy, SNUG01, for the treatment of amyotrophic lateral sclerosis (ALS). SNUG01 is a first-in-class gene therapy targeting
More news about: SineuGene Therapeutics
Jun 26, 2025, 09:53 ET Kalorama Information Releases 2025 IVD Market Update: Innovation and Growth Surge in Clinical Chemistry, Immunoassays, and Molecular Diagnostics
industry leaders navigating the changing IVD landscape. It covers core growth areas such as point-of-care (POC) diabetes testing, nucleic acid assays, gene testing, companion diagnostics, mass spectrometry, and HPV molecular diagnostics. "From the perspective of conventional markets, revenues have
More news about: Kalorama Information
Jun 26, 2025, 09:30 ET Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365
More news about: Emmaus Life Sciences, Inc.
Jun 26, 2025, 09:00 ET Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa
A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. SUZHOU, China and CAIRO,
More news about: Porton Advanced Solutions
Jun 26, 2025, 07:30 ET Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease
dysfunction to solve complex diseases. The Company's proprietary drug discovery platform leverages advanced transcriptomics to comprehensively understand gene networks and applies the power of dynamic AI modeling to predict and design oral Cell State-Correcting therapeutics that can precisely regulate genetic
More news about: Cellarity
Jun 26, 2025, 07:00 ET Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from retinal degenerative diseases, today announced the formation of its
More news about: Nanoscope Therapeutics
Jun 26, 2025, 06:00 ET Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
participants with Duchenne who have been previously treated with gene therapy. FOX participants are on average over 10 years old and four years out from receiving gene therapy. Despite the lack of extensive natural history in Duchenne gene therapy treated boys, initial results from the FOX study indicate
More news about: Edgewise Therapeutics
Jun 25, 2025, 14:11 ET Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
the stem cells to grow into specific tissue types. The stem cells can be generic or come from specific individuals with health conditions and can be gene-edited before beginning the process. Cincinnati Children's has been a leader in organoid research since 2010 when experts here developed the
More news about: Cincinnati Children's Hospital Medical Center
Jun 25, 2025, 11:20 ET Liver Disease Treatments: Global Market Forecast and Emerging Trends Through 2030
global cases of liver diseases like cirrhosis, hepatitis, and NAFLD, driven by increasing obesity, diabetes, and alcohol use. With new treatments like gene therapy and personalized medicine emerging, and regulatory changes reshaping the market, it is more crucial than ever for healthcare providers, investors,
More news about: BCC Research LLC
Jun 25, 2025, 10:39 ET Madison Ranked as Best Metro Area for 'Functional Employment' by Ludwig Institute
@LISEP_org. About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder
More news about: Ludwig Institute for Shared Economic Prosperity
Jun 25, 2025, 09:30 ET Multistakeholder Consortium Unveils Systems-Level Roadmap to Transform Obesity Disease Management
international think and do tank at Tufts Medical Center, has previously led initiatives in precision medicine and financing innovation for cell and gene therapies. The obesity roadmap continues this tradition of bringing together diverse stakeholders to solve complex healthcare challenges that no single
More news about: CBSD at Tufts Medicine
Jun 25, 2025, 08:00 ET Avance Biosciences Launches NGS Center of Excellence in Houston
drug modalities including biologics, RNA therapeutics, and cell and gene therapies. "This is a major milestone for Avance Biosciences as we continue to support the evolving needs of biologics and cell and gene therapy developers," said Xuening Huang,
More news about: Avance Biosciences, Inc.
Jun 25, 2025, 06:00 ET Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry's Interdisciplinary Prize
excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve's gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targetsSOUTHAMPTON,
More news about: Curve Therapeutics
Jun 24, 2025, 20:01 ET RBLP Leadership Certifications Receive Prestigious American Council on Education (ACE) College Credit Recommendations
University Network. "We are honored to receive ACE college credit recommendations for our certification exams," said Dr. Gene Coughlin, the Founder and CEO of RBLP. "This recognition from ACE is a testament to the academic rigor and real-world impact of our program."
More news about: RBLP Leadership Certifications
Jun 24, 2025, 15:06 ET Breakthrough T1D Joins Diabetes Leaders at the American Diabetes Association 85th Scientific Sessions to Highlight Research Advancements
gave an update on the individual with T1D who received a transplant of deceased donor islets that were gene-edited with Sana's Hypoimmune (HIP) technology. HIP technology makes the cells immune-evasive, meaning they are not destroyed by the body's immune system.
More news about: Breakthrough T1D, Formerly JDRF
Jun 24, 2025, 14:30 ET Two Children Dead After Gene Therapy: Florida Attorney Raises Alarms About FDA Oversight
/PRNewswire/ -- A second child has died after receiving Elevidys, an experimental gene therapy for Duchenne muscular dystrophy—raising serious concerns about regulatory shortcuts, patient safety, and the urgent need for oversight.
More news about: Rafferty Domnick Cunningham & Yaffa
Jun 24, 2025, 14:09 ET Five University of Colorado Cancer Center Advancements That Changed the Game for Patients
Steven Dow, DVM, PhD, "The cells eradicate the cancerous tumor with the aim to make sure it doesn't recur." Testing for gene mutations in lung cancer Not all
More news about: University of Colorado Anschutz
Jun 24, 2025, 14:00 ET Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
About PhenylketonuriaPhenylketonuria (PKU) is a rare, inherited metabolic disease, which affects the brain. It is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine (Phe). If left untreated or poorly managed, Phe — an essential amino acid found in all
More news about: PTC Therapeutics, Inc.
Jun 24, 2025, 14:00 ET Sephience™ (sepiapterina) recebeu autorização para comercialização da Comissão Europeia para o tratamento de crianças e adultos com fenilcetonúria (PKU)
fenilcetonúria A fenilcetonúria (PKU) é uma doença metabólica rara e hereditária que afeta o cérebro. A causa da doença é um defeito no gene que ajuda a criar a enzima necessária para decompor a fenilalanina (Phe). Se não for tratada ou se for mal controlada, a fenilalanina, um aminoácido
More news about: PTC Therapeutics, Inc.
Jun 24, 2025, 12:08 ET Ovarian Cancer Drugs Market Size expected to reach US$ 4.23 billion by 2031 | The Insight Partners
inhibitors such as olaparib, rucaparib, and niraparib, are particularly effective for specific types of ovarian cancer, especially those associated with BRCA gene mutations. Additionally, mirvetuximab soravtansine is a monoclonal antibody that is used for recurrent ovarian cancer. The report runs an in-depth
More news about: The Insight Partners
Jun 24, 2025, 10:44 ET Kicking Off Today! Process Intensified. Drug Manufacturing Accelerated. The Sartorius PI Forum opens in Boston -- shaping biomanufacturing's future
Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales
More news about: Sartorius
Jun 24, 2025, 10:30 ET Label-free Detection Market to Accelerate Growth from USD 2.64 Billion to USD 4.48 Billion by 2032 - Meticulous Research®
drug discovery. Gene Therapy Development Shows Highest Growth Potential The gene therapy development segment exhibits the strongest growth trajectory at 16.7% CAGR, driven by increasing adoption of label-free detection technologies for characterizing gene therapy products, monitoring
More news about: Meticulous Market Research Pvt. Ltd.
Jun 24, 2025, 10:00 ET Vector BioMed and Muni Seva Ashram Partner to Bring CAR-T Cell Therapy to Rural India
/PRNewswire/ -- Vector BioMed, a purpose-driven contract vector development and manufacturing organization (CVDMO) focused on advancing access to cell and gene therapies, today announced a strategic partnership with Muni Seva Ashram's Kailash Cancer Hospital and Research Center (KCHRC) in Gujarat, India.
More news about: Vector BioMed